We’re on a mission to make early liver cancer detection as routine as a cholesterol test.
Every year, tens of thousands of Americans die from liver cancer. Outcomes depend strongly on the stage at which the cancer is detected, making earlier detection especially important for people at increased risk.
MoleculeDx was founded to help address this challenge. Our approach uses cancer-associated fusion transcripts detected in blood together with a computational classification model to identify molecular signals associated with hepatocellular carcinoma (HCC).
Our Fusion-detect™ technology provides a simple, non-invasive blood-based approach for liver cancer detection by identifying HCC-associated fusion transcript signals in patients at risk for liver cancer.
Hepatocellular carcinoma can harbor cancer-associated fusion genes created by chromosomal rearrangements. Fusion transcripts produced from these genomic alterations can be released into the bloodstream, providing highly specific molecular signals that can be detected using sensitive RNA-based methods.
Our test detects cancer-associated cell-free fusion transcripts in serum. These fusion transcripts originate from chromosomal rearrangements associated with hepatocellular carcinoma and provide distinctive molecular signals for HCC detection.
Fusion-detect™ combines signals from multiple fusion transcripts using a computational classification model to distinguish HCC-associated molecular patterns from non-HCC patterns.
Patient samples are processed in MoleculeDx’s CLIA-certified, COLA-accredited clinical laboratory using standardized laboratory procedures and quality controls.
Ordering takes only a few minutes. At-home blood collection is available through our contracted phlebotomy partners. Liver cancer can develop without noticeable symptoms, making screening particularly important for people at increased risk.
Learn more about MoleculeDx, our laboratory, technology, expertise, research, and commitment to liver cancer detection.
Our mission is to make accurate, accessible blood-based liver cancer detection available to people at risk for hepatocellular carcinoma, helping identify cancer earlier when treatment options may be more effective.
MoleculeDx was founded in June 2024 to translate advances in molecular cancer biology into practical blood-based diagnostic tests, with an initial focus on improving the detection of hepatocellular carcinoma (HCC).
MoleculeDx is a molecular diagnostics company focused on blood-based cancer detection. We operate a CLIA-certified, COLA-accredited clinical laboratory and a digital platform that enables patients and healthcare providers to order tests, coordinate blood collection, and access test results.
MoleculeDx is supported by a multidisciplinary team with expertise in molecular diagnostics, cancer biology, bioinformatics, clinical laboratory testing, and healthcare operations. This combination of scientific, clinical, and operational expertise supports the development and delivery of blood-based molecular testing for liver cancer detection.
MoleculeDx operates a CLIA-certified clinical laboratory accredited by COLA. These credentials demonstrate that our laboratory meets applicable federal requirements and recognized standards for quality, accuracy, and reliability in clinical laboratory testing.
MoleculeDx performs testing in its CLIA-certified, COLA-accredited clinical laboratory using standardized laboratory procedures and quality controls. Testing includes defined specimen-handling procedures, assay controls, and quality checks designed to support consistent and reliable results.
MoleculeDx protects patient information using secure, access-controlled systems and safeguards designed to comply with applicable healthcare privacy requirements. Access to patient information is limited to authorized personnel involved in testing, laboratory operations, and patient or provider support.
Yes. MoleculeDx’s technology is grounded in peer-reviewed research on cancer-associated fusion genes and circulating fusion transcripts in hepatocellular carcinoma (HCC). We continue to advance this work through clinical studies and research collaborations focused on improving blood-based detection of liver cancer.
For general questions, patient inquiries, or healthcare provider inquiries, please contact MoleculeDx through our Contact Us page. Healthcare providers and organizations interested in working with MoleculeDx may also contact our partnerships team at partners@moleculedx.com.
© 2026 MoleculeDx Inc. All rights reserved.
Test results should be interpreted in the context of other clinical information and are not a substitute for evaluation by a qualified healthcare provider.
